| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income/(loss) | 81,339 | -134,376 | -92,225 | -161,525 |
| Share-based compensation expense | 82,757 | 54,571 | 27,374 | 87,814 |
| Loss on extinguishment of development liability | - | - | - | 1,949 |
| Depreciation expense | 1,231 | 892 | 446 | 1,350 |
| Amortization of discounts for credit facility | 1,602 | 1,046 | 512 | 742 |
| Amortization of discounts for convertible notes | 239 | 159 | 79 | 230 |
| Accretion of discount to development liability | - | - | - | 8,936 |
| Accounts receivable | 80,605 | -50,798 | -29,680 | 72,569 |
| Inventory | 6,609 | 12,011 | -13,997 | 20,776 |
| Prepaid assets | 13,157 | 10,773 | 18,726 | -15,022 |
| Other current assets | -1,642 | 8,145 | 1,307 | -10,651 |
| Other assets | 4,181 | -259 | -198 | 81 |
| Right-of-use assets and lease liabilities | 109 | 222 | 7 | -7 |
| Accounts payable | 28 | 15,666 | 16,711 | -399 |
| Accrued expenses | -198 | -7,273 | -30,156 | 19,534 |
| Other current liabilities | 0 | - | - | - |
| Deferred revenue | - | - | - | 1,903 |
| Other liabilities | -4,694 | - | - | - |
| Net cash provided by/(used in) operating activities | 59,503 | -48,965 | -53,410 | -107,226 |
| Purchase of property and equipment | 205 | 57 | 8 | 383 |
| Net cash used in investing activities | -205 | -57 | -8 | -383 |
| Proceeds from credit facility | - | - | - | 365,454 |
| Payment of issuance cost for credit facility | - | - | - | 1,589 |
| Repayment of development liability | - | - | - | 326,533 |
| Proceeds from settlement of capped call | - | - | - | 98,763 |
| Proceeds from exercise of stock options | 5,445 | 4,648 | 281 | 13,995 |
| Proceeds from issuance of common stock under employee stock purchase plan | 2,191 | 2,191 | - | 3,193 |
| Payments of employee tax withholding related to equity-based compensation | 11 | 7 | 7 | 42 |
| Net cash provided by financing activities | 7,625 | 6,832 | 274 | 153,241 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,066 | 1,044 | 359 | 306 |
| Net (decrease)/ increase in cash, cash equivalents and restricted cash | 67,989 | -41,146 | -52,785 | 45,938 |
| Cash and cash equivalents at beginning of period | 412,612 | 412,612 | 412,612 | 352,299 |
| Cash and cash equivalents at end of period | 480,601 | 371,466 | 359,827 | 398,237 |
Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. (APLS)